Bull wins on forward fundamentals: ~16× forward P/E on ~21% projected EPS growth yields PEG near 1.0, backlog is strong ($1.2B PrSM award, JATM framework, PAC-3/THAAD volume, F-35 Germany rollout), balance sheet improving (cash tripled YoY, net debt down 17.6%, interest coverage 8.4×, FCF yield ~4.6%), and 2.6% dividend well-covered. Bear wins on technical breakdown: price below 50 SMA, 200 SMA, 10 EMA, and VWAP with death cross forming near $554; two-year delivered EPS decline ($27.55 → $22.31 → $21.49) is a real trend; Q2 2026's $7.94 print encouraging but not a confirmed reversal; margin recovery to 12.4% still below 2022 peak of 12.7%; cost of revenue up 23% YoY; sector de-rating compounds stock-specific headwind. Synthesis: quality business in confirmed near-term downtrend; market voting against forward EPS recovery; bull's probability weights (35% bull / 50% base / 15% bear) too generous given failed $554 tests; bear's weighting (25% / 45% / 30%) more realistic, collapsing expected return to roughly dividend yield.

POSITION MANAGEMENT FOR CURRENT HOLDERS: Trim existing LMT exposure by 25–50% into any relief rallies toward $545–555 (the 50/200 SMA cluster). Do not average down below current levels. Retain a core position to collect the 2.6% dividend yield (well-supported by 8.4× interest coverage and $5.56B TTM FCF) while awaiting a technical reset.

RE-ENTRY FRAMEWORK FOR THE TRADER: Primary buy zone: $470–500 — combines April low ($497), round-number psychological support at $500, and would reset technical structure (RSI oversold, MACD reset, Bollinger band re-expansion). Add 25% of intended position size on confirmed bounce with volume confirmation. Secondary buy zone: $440–460 — full conviction re-entry if Q3 2026 earnings or Hormuz de-escalation triggers bear-case scenario; backlog thesis intact, valuation closer to 13× forward earnings.

RE-ENTRY TRIGGER: Reclaim of $555 on above-average volume AND positive MACD histogram cross — invalidates death cross formation and justifies returning to Hold/Overweight.

RISK MANAGEMENT: Hard stop on any new tranches: $437 (52-week low) on a closing basis — break below signals structural thesis break requiring full re-evaluation. Avoid adding above $530 — every test of descending resistance line since February has failed; path of least resistance remains lower until proven otherwise. Size new positions at half-normal weight until technical structure confirms base (higher low + higher high sequence on daily chart).

CATALYSTS TO MONITOR FOR RATING CHANGE: 1) Q3 2026 earnings — focus on MFC segment margin expansion; print below $7.20 EPS with margin compression below 12% would force downgrade to Sell. 2) CR/DoD budget resolution — clean full-year FY2027 appropriations would be positive catalyst; another full-year CR would pressure deliveries. 3) Hormuz resolution — confirmed de-escalation likely accelerates sector de-rating. 4) F-35 Block 4 software milestones — successful delivery would relieve program overhang.

TIME HORIZON: 3–6 month trim-and-wait call. Re-evaluate to Hold or Overweight if price reclaims $555 with volume, or to Buy if price reaches $470–500 zone with technical confirmation.

The Research Manager's plan explicitly calls for an Underweight stance with a "trim and wait" directive, which I translate into a Sell (trim) action. The technical structure is unambiguously bearish: price is below the 50 SMA, 200 SMA, 10 EMA, and VWMA simultaneously, with the 50/200 SMAs converging into a potential death cross near $554 — a level that has rejected multiple rally attempts since February. The delivered EPS trajectory ($27.55 → $22.31 → $21.49) confirms a two-year downtrend that Q2 2026's $7.94 print has not yet reversed, and the defense sector is independently de-rating. While the fundamental thesis (backlog, balance sheet, dividend) remains intact and warrants retaining a core position, adding exposure above $530 fights the tape and ignores the plan's explicit guidance to avoid that level. Selling into relief rallies toward the $545–555 SMA cluster aligns with the plan's strategic actions.

Stop loss: $555.00

Sizing: Trim 25–50% of existing LMT exposure into rallies toward $545–555; retain core position for dividend income (~2.6% yield). New tranches sized at half-normal weight only if price reaches the $470–500 buy zone with technical confirmation.